UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

20 Closing gaps in HS care through community engagement and scientific innovation

Read More Share:

Nov

20 UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Read More Share:

Sep

27 UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

Read More Share:

Aug

16 UCB Elevates Hidradenitis Suppurativa Awareness with Inaugural Patient and HCP Summit with Special Appearance by Dr. Sandra Lee (AKA "Dr. Pimple Popper")

Read More Share:

May

23 UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa

Read More Share:

Apr

10 UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa

Read More Share:

Apr

04 FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

Read More Share:

Mar

08 BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

Read More Share:

Oct

13 UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

Read More Share:

Oct

13 Going Beyond the Medicine: How UCB Is Addressing the Needs of People Living with Hidradenitis Suppurativa

Read More Share:

Categories

Archives

Nov

20

Closing gaps in HS care through community engagement and scientific innovation

Nov

20

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Sep

27

UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

Aug

16

UCB Elevates Hidradenitis Suppurativa Awareness with Inaugural Patient and HCP Summit with Special Appearance by Dr. Sandra Lee (AKA "Dr. Pimple Popper")

May

23

UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa

Apr

10

UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa

Apr

04

FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

Mar

08

BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

Oct

13

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

Oct

13

Going Beyond the Medicine: How UCB Is Addressing the Needs of People Living with Hidradenitis Suppurativa

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Nov

20

Closing gaps in HS care through community engagement and scientific innovation

Nov

20

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Sep

27

UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

Aug

16

UCB Elevates Hidradenitis Suppurativa Awareness with Inaugural Patient and HCP Summit with Special Appearance by Dr. Sandra Lee (AKA "Dr. Pimple Popper")

May

23

UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa

Apr

10

UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa

Apr

04

FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

Mar

08

BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

Oct

13

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

Oct

13

Going Beyond the Medicine: How UCB Is Addressing the Needs of People Living with Hidradenitis Suppurativa

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact